KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Non Operating Income (2018 - 2025)

Acadia Pharmaceuticals (ACAD) has 8 years of Non Operating Income data on record, last reported at $596000.0 in Q4 2025.

  • For Q4 2025, Non Operating Income rose 103.98% year-over-year to $596000.0; the TTM value through Dec 2025 reached $2.4 million, up 117.29%, while the annual FY2025 figure was $2.4 million, 117.29% up from the prior year.
  • Non Operating Income reached $596000.0 in Q4 2025 per ACAD's latest filing, up from $593000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $4.8 million in Q1 2023 and bottomed at -$15.0 million in Q4 2024.
  • Average Non Operating Income over 5 years is -$791200.0, with a median of $384500.0 recorded in 2021.
  • Peak YoY movement for Non Operating Income: plummeted 379.21% in 2022, then soared 1325.0% in 2023.
  • A 5-year view of Non Operating Income shows it stood at $2.2 million in 2021, then crashed by 284.57% to -$4.0 million in 2022, then plummeted by 156.55% to -$10.2 million in 2023, then crashed by 46.91% to -$15.0 million in 2024, then soared by 103.98% to $596000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were $596000.0 in Q4 2025, $593000.0 in Q3 2025, and $594000.0 in Q2 2025.